NCT07287527 Effects of Photobiomodularion on Brain Connectivity and Cognitive Function in Cognitive Impairment
| NCT ID | NCT07287527 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Uskudar University |
| Condition | AMCI - Amnestic Mild Cognitive Impairment |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-03-30 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-03-30 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if transcranial photobiomodulation (t-PBM), a light-based brain therapy, can help improve memory and cognitive skills in older adults with amnestic mild cognitive impairment (aMCI). This condition involves memory problems that are greater than normal aging and may increase the chance of developing Alzheimer's disease. The main questions this study aims to answer are: 1. Does t-PBM, when used together with cognitive training, improve memory and cognitive skills? 2. Does t-PBM change how certain brain areas communicate with each other, especially in the default mode network (DMN)? Researchers will compare: t-PBM plus cognitive training to sham (inactive) t-PBM plus the same cognitive training to see if the active light treatment leads to better cognitive improvement and healthier brain activity. Participants will: * Provide a blood sample so the research team can create a genetic profile; * Complete cognitive tests before and after the 4-week program; * Meet with a dietitian before and after the program so the research team can make sure diet stays consistent and does not influence brain results; * Have a brain fMRI scan before and after treatment to measure brain connectivity changes; * Take part in eight sessions of cognitive training; * Receive either active t-PBM or sham t-PBM during these sessions.
Eligibility Criteria
Inclusion Criteria: * Age 55 years or older * Diagnosis of amnestic Mild Cognitive Impairment (aMCI) Exclusion Criteria: * Presence of a neurological disorder * Presence of a severe psychiatric disorder * Having a pacemaker or other implanted medical device that is not MRI-compatible
Contact & Investigator
Baris Metin, Prof. Dr.
PRINCIPAL INVESTIGATOR
Uskudar University
Frequently Asked Questions
Who can join the NCT07287527 clinical trial?
This trial is open to participants of all sexes, aged 55 Years or older, studying AMCI - Amnestic Mild Cognitive Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07287527 currently recruiting?
Yes, NCT07287527 is actively recruiting participants. Contact the research team at shams.farhad@uskudar.edu.tr for enrollment information.
Where is the NCT07287527 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye), Istnabul, Turkey (Türkiye).
Who is sponsoring the NCT07287527 clinical trial?
NCT07287527 is sponsored by Uskudar University. The principal investigator is Baris Metin, Prof. Dr. at Uskudar University. The trial plans to enroll 60 participants.